Initiated 2026-10-18 · Price $207.36 (as of 2026-10-16, stockanalysis.com) · Mkt cap $10.8bn (52.2mm shares) · Health care / managed care (Medicaid, Medicare duals, ACA Marketplace) · Model: verified

Rating: Hold — Conviction: Low

Molina's recovery is credible: 2026 should be the trough, and with Florida start-up costs and MAPD losses not recurring, management's 2027 building blocks exceed $10 a share, about double 2026's ≥$5.25. But the stock has already rallied ~70% off its 52-week low, and at ~20x those building blocks it prices a good part of the recovery. What isn't priced is the risk in a 1–2% margin, mostly-Medicaid book carrying ~47% debt-to-capital: state rates are still running about a point below trend, work requirements start in 2027, and in Q2 the company cut its Marketplace outlook by $1.50 a share after another miss.

Conviction tests (3a-v-c): T1 fail (Hold → Buy at −1pp: Base +49.0%; +6.5% at +1pp) · T2 fail (Gordon alone +45% reads Buy; exit-multiple alone +3% reads Hold) · T3 pass · T4 pass (no pending deal, ruling or single-contract event worth >25%; the securities class action was dismissed with leave to amend; the 2026-10-21 Q3 print and 2027 outlook sit inside the cases)

Business overview

Molina is a government-sponsored health plan. FY2025 total revenue was $45.4bn, of which $43.1bn was premium. At 2026-06-30 it had 4.9mm members: Medicaid 4.42mm (about four-fifths of premium), Medicare 224k (mostly dual-eligibles), and Marketplace 283k, down from 690k a year earlier. Model-basis margin, which includes investment income on the float, was ~5% in 2023–24 and 2.2% in FY2025, and 2026 runs near 1.4%. Three variables drive earnings. First, state Medicaid rates vs cost trend: 2026 rates are ~4% against ~5% trend, and each 100bp of Medicaid MCR is worth ~$5 a share. Second, new contracts reaching target margin, chiefly the ~$6bn-a-year Florida children's contract starting in Q4 2026 (embedded earnings ~$9 a share per management). Third, the Marketplace, being shrunk toward breakeven.

Competition

In Medicaid managed care, Molina held 6% of HMAIS-tracked enrollment in June 2026. Centene had 17.9%, Elevance 10.7% and UnitedHealth 8%, in a market that shrank 5.5% year on year to 59.2mm as redeterminations continued (Health Management Associates, Q2 2026). The pressure shows up in rates and acuity, not price competition. Molina reports a >90% re-procurement win rate and recently retained Illinois (~$2bn). Centene, its closest listed comparable, trades at 14.9x forward earnings against Molina's 29.5x on depressed profits; Elevance trades at 15.8x and UnitedHealth at 17.7x (stockanalysis.com, 2026-10-16).

Bull case

1. Medicaid margin repair — 2026 is the trough. As ~55% of premium reprices each January and states fund acuity, Medicaid MCR improves faster than the ~90bp over three years management assumes. Plays out if 2027 rate updates exceed trend by 50bp or more. Model: ebitda_margin
2. New-store growth converts to earnings — Florida and other wins carry premium to the $46.5bn 2027 outlook and toward the $64bn 2029 target, and embedded earnings emerge on schedule. Plays out if Florida breaks even in its first full year, as guided. Model: rev_growth, ebitda_margin
3. Re-rating on normalized earnings — at ~3.8% margins, the growth record earns an 11x exit and 3% terminal growth. Model: exit_ev_ebitda, terminal_growth

Bear case

1. Rates keep lagging a sicker book — work requirements and redeterminations remove healthier members from 2027 faster than states reprice; management itself calls the market ~300bp underfunded. Revenue growth falls to 2–3% after Florida, and margin stays near 2%. Plays out if Medicaid MCR stays above ~92% through 2027. Model: rev_growth, ebitda_margin
2. Execution and guidance credibility — the Marketplace missed again in Q2 (MCR 88.9%), and new contracts lose money before reaching target margin. Plays out if Florida runs above breakeven MCR in 2027 or the Marketplace loses money again. Model: ebitda_margin
3. Policy discount on a levered balance sheet — S&P cut the notes to BB- in April 2026. Debt-to-capital is ~47%, and parent cash was only $290mm. A higher risk premium (8.9% WACC) and a 7.0x exit compress the equity. Model: wacc, exit_ev_ebitda

Valuation & balance sheet

The aggregator's 25.1x EV/EBITDA nets ~$8.9bn of mostly regulated cash against debt.

Model-implied value range (from model-summary.json; generic module, Gordon-growth DCF and exit-EV/EBITDA DCF, midpoints): Bear $62.39 · Base $257.72 · Bull $462.56 per share, i.e. implied returns of −69.9% / +24.3% / +123.1% vs $207.36. These ranges show how the bull and bear drivers translate into value; they are not price targets.

• What's priced in. The price is ~74% of the way from Bear to Base.
• Re-rating. The Base exit of 9.0x is a de-rating from today's 14.9x FY2025 multiple (23.5x 2026E). The two methods differ by 40% (Gordon $301.18, exit $214.27). Gordon embeds the much higher terminal multiple, so the re-rating, and nearly all of the base upside, sits in that method.
• Why Hold despite a +24% Base. On the exit method alone the stock is roughly fair (+3%); the Gordon upside rests on a terminal multiple above what the 2023–24 earnings base supported. The bear case is −70% and the tail is zero, on a company whose shares fell 57% in the year to April 2026 on margin misses. The return doesn't pay enough for that skew.
• Tail. Revenue flat in 2027, −4% in 2028 and flat in 2029, margin 1.2–1.5%, NWC −2%, 9.5% WACC, a 6.0x exit and 1% terminal growth give $0.00 (floored): equity value doesn't cover net debt.

Balance sheet: net leverage 3.6x model-basis FY2025 EBITDA (gross 3.9x), ~5.5x on the model's 2026E. Coverage 5.1x. Liquidity: ~$290mm parent cash (~$600mm guided for year-end) and an undrawn $1.25bn revolver to 2030. Debt-to-capital ~47%, guided to ~44% at year-end. Nearest maturity: $800mm of 4.375% notes due June 2028. Ratings: S&P BB- (cut from BB in April 2026), Moody's Ba2.

Model note: tier full, status built, verification verified (3,207 formula cells matched in LibreOffice). No unverified inputs and no assumptions without a basis. Scenario consistency is OK on all 14 rows.

• Sourcing. Historicals from the FY2025/FY2024 10-Ks (EDGAR); debt, shares, ratings and guidance from the Q2 10-Q and release; parent cash from the Q2 call.
• EBITDA basis. Investment income is included and only parent cash is netted. Acquisition-related and "other" costs stay in EBITDA. Capex includes ~0.25% of revenue for statutory capital retention (judgment).
• EPS vs guidance. Base Y1 EPS of $4.57 is 13% below the ≥$5.25 adjusted guide. The model keeps the $1.24 a share of acquisition-related costs and the $0.41 of other costs, deducts $0.71 of amortization, and uses 52.2mm shares rather than 51.1mm. Base Y2 EPS of $11.60 is consistent with the >$10 building blocks plus modest Medicaid repair.
• WACC. 7.9% = CAPM cost of equity 8.99% (10Y 5.09%, beta 0.78, 5% ERP, no premium) and 4.81% after-tax debt (est.) at a 27% market weight; computes to 7.87%. The low 5-year beta likely flatters the cost of equity; T1 shows the call is sensitive to it.

Scenario stress test

Reasoned from the bull/bear drivers above. The model column comes from the scenario overlays (Base case + shock).

Currently active/on watch per the playbook: S3 partially active (price-level leg only); S8, S10 and S11 on watch.

What would change the call

Upgrades if: 2027 guidance (likely with Q4 results, ~February 2027) confirms >$10 adjusted EPS with Medicaid MCR at or below 92% and Florida on track to break even, or the price falls toward the lower half of the Bear–Base range with no change in fundamentals. Downgrades if: Medicaid MCR rises above 93% for two quarters, Florida start-up losses run past 2026, the Marketplace loses money again in 2027, or debt-to-capital fails to fall toward 44%.

Watch items

• W1: Q3 2026 Medicaid MCR and full-year guide — Medicaid MCR ≤93% and ≥$5.25 reaffirmed or raised — Q3 2026 release — 2026-10-21 — Model: ebitda_margin
• W2: 2027 outlook — premium ~$46.5bn and adjusted EPS >$10 confirmed — Q4 2026 release — ~February 2027 — Model: rev_growth, ebitda_margin
• W3: January 2027 Medicaid rate updates — composite above ~5% trend — Q4 2026 call / Q1 2027 10-Q — ~February–April 2027 — Model: ebitda_margin
• W4: Parent cash and leverage — parent cash ~$600mm and debt-to-cap ~44% at YE2026 — Q4 2026 release — ~February 2027 — Model: none

Sources

• Molina statistics, stockanalysis.com — https://stockanalysis.com/stocks/moh/statistics/ — accessed 2026-10-18
• Molina XBRL Revenues, EDGAR — https://data.sec.gov/api/xbrl/companyconcept/CIK0001179929/us-gaap/Revenues.json — accessed 2026-10-18
• Molina FY2025 10-K statements of income, balance sheet and cash flows (acc. 0001179929-26-000005) — https://www.sec.gov/Archives/edgar/data/1179929/000117992926000005/R3.htm (R5, R7, R8) — accessed 2026-10-18
• Molina FY2024 10-K balance sheet (acc. 0001179929-25-000023) — https://www.sec.gov/Archives/edgar/data/1179929/000117992925000023/R5.htm — accessed 2026-10-18
• Molina Q2 2026 earnings release (8-K) — https://www.sec.gov/Archives/edgar/data/0001179929/000117992926000036/moh2q26_er.htm — accessed 2026-10-18
• Molina Q2 2026 Form 10-Q — https://www.sec.gov/Archives/edgar/data/0001179929/000117992926000039/moh-20260630.htm — accessed 2026-10-18
• Molina Q2 2026 earnings call transcript — https://earningswhispers.com/transcript/MOH/Q22026 — accessed 2026-10-18
• Notes and ratings, Q3 date, September price action and lawsuit dismissal (via search summaries) — https://business.minstercommunitypost.com/minstercommunitypost/article/bizwire-2025-11-20-molina-healthcare-announces-closing-of-offering-of-850-million-of-6500-senior-notes-due-2031 ; https://finance.yahoo.com/healthcare/articles/diamond-hill-capital-sees-long-110108325.html ; https://www.marketbeat.com/instant-alerts/price-molina-healthcare-nyse-moh-shares-climb-5-should-you-buy-2026-10-12/ ; https://www.tikr.com/blog/molina-healthcare-stock-forecast-where-analysts-see-the-stock-going-by-2027 — accessed 2026-10-18
• Medicaid market share, HMA Q2 2026 — https://www.healthmanagement.com/blog/medicaid-managed-care-enrollment-declines-in-q2-2026-hma-analysis-of-state-trends-and-market-share/ — accessed 2026-10-18
• CNC, ELV, UNH statistics, stockanalysis.com — https://stockanalysis.com/stocks/cnc/statistics/ (and /elv/, /unh/) — accessed 2026-10-18
• 10Y Treasury 5.09% (2026-10-16) — logs/macro-2026-10.md (Treasury.gov par curve)